Inovio could take malaria vaccine to human trials next year

08/15/2013 | American City Business Journals

Inovio Pharmaceuticals has announced that its SynCon DNA malaria vaccine elicited lasting antibody and T-cell immune responses in animal studies. A clinical study is expected to begin next year. "We have now generated strong immunology data with our malaria vaccine in nonhuman primates. We are excited to advance toward the very important health care goal of conquering malaria," Inovio President and CEO Dr. J. Joseph Kim said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC